|
Post by nicktrantx on Aug 13, 2014 10:44:22 GMT -5
You can call me stupid but I have several item on the list to ask and hoping for feedback. comment.
1. Sanofi offered around $1billion for the partnership granted by milestone payment -why everyone keep saying $150mil? 2. Expiration date for the partnership - we have not heard one yet . Will we have one? I hope it'll be. 3. This is Afrezza partnership and not the Technosphere application. So why look so down by many? 4. Can MNKD re-negotiate the agreedment?
As the old saying, we'll see sunshine after the rain.
Cheer!
Nick
|
|
|
Post by dubylvs on Aug 13, 2014 10:58:45 GMT -5
Hope this helps you undestand the terms of the deal...
U.S.-based MannKind will receive an upfront payment of $150 million and potential further milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65 percent and MannKind the rest.
|
|
|
Post by brentie on Aug 13, 2014 11:24:44 GMT -5
It's the old "Don't count your chickens before they're hatched". This article discusses it. "Now let me shift gears a bit and look at the $775 million in milestones that was announced as part of the deal. These are potential payments that MannKind can earn when certain regulatory and sales goals are met. When I look at milestones in deals, I often look at it is a very simple manner. The first third of that money is essentially money in the bank. The second third is earned with good success. The last third requires "uber-success" to be earned. Rarely are all targets in a deal like this earned. While very simple, this model has served me very well over the years. In essence, look for $260 million to be easy to obtain, $260 million to be harder to obtain and the last $260 million to be at a level that everyone is swimming in money anyway, and the milestones will be a small part of the excitement." seekingalpha.com/article/2418605-a-deeper-look-at-mannkind-sanofi-deal-and-valuation
|
|